Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IL-4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
NY (what is this?) (verify) |
Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 2001/2002.[2]
References
- ^ Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
- ^ Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
|
IL-1 |
| ||||
---|---|---|---|---|---|
IL-2 | |||||
IL-3 | |||||
IL-4 |
| ||||
IL-5 |
| ||||
IL-6 |
| ||||
IL-7 |
| ||||
IL-8 |
| ||||
IL-9 |
| ||||
IL-10 |
| ||||
IL-11 |
| ||||
IL-12 |
| ||||
IL-13 |
| ||||
IL-15 |
| ||||
IL-17 |
| ||||
IL-18 |
| ||||
IL-20 |
| ||||
IL-21 |
| ||||
IL-22 |
| ||||
IL-23 |
| ||||
IL-27 |
| ||||
IL-28 | |||||
IL-31 |
| ||||
IL1RL1 |
| ||||
IL1RL2 |
| ||||
Others |
| ||||
- This page was last edited on 16 February 2020, at 07:49 (UTC).
- Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.